Grant: Alliance Grants
University of Toronto
$249,700.00
Quantum sensors for biophysical modelling of brain function
FY 2024-25
Summary
Brain disorders represent the biggest challenge for 21st century healthcare, with a barrier to effective management being a lack of technologies to objectively assess brain health and disease. In many conditions the underlying issue is functional, due to pathological brain electrochemistry. This is harder to measure and the gold-standard for measuring brain electrochemistry is to place electrodes in the brain, which is highly invasive. Non-invasive techniques rely on measuring electrical signals at the scalp (EEG) or magnetic fields generated by neural currents (MEG). EEG has a limited spatial resolution and sensitivity to 'high-frequency' signals which are markers of healthy brain function. MEG has a good spatial precision, yet classic systems lack sensitivity and practicality. Quantum enabled magnetic field sensors - called optically pumped magnetometers - promise game-changing advancements in assessment of brain function, lifting the restrictions surrounding MEG, with simulations showing that OPM-MEG could rival the sensitivity of invasive techniques. This increased SNR also comes at a low cost, increased practicality, and greater scan tolerability, even enabling head-free movement. Our vision is to develop a quantum sensor-based imaging system for biophysical modelling of brain data, enabling electrophysiology with precision and sensitivity not possible before in non-invasive imaging, improving mathematical modeling of brain data, elucidating the electrochemical activity that underlies functioning. We will build the first quantum enabled scanner tailored to biophysical modelling and develop algorithms to exploit this increased sensitivity, testing our new system in two ways: first, in a neuropharmacological study of brain chemistry with alcohol administration. Second, we will measure how brain chemistry matures across development. These studies will prove the principle and value of biophysical modelling, exploiting the unique capabilities of quantum sensors for brain function. Ultimately, this will be transformative in human neuroscience and the technology we develop will find use in drug development, improving success rates in clinical trials, and moving the needle on precision medicine.
Program
Alliance Grants
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
597836-2024
Name nom
Dunkley, Benjamin T
Department département
Pharmacology and Toxicology
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2024
Competition year année de concours
2024
Award amount
249700
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1202
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Physical sciences
Area of application fr
Sciences physiques
Research subject code
3114
Research subject group en
Physics
Research subject group fr
Physique
Research subject en
Biological and Medical Physics
Research subject fr
Physique biologique et médicale
Field of research list names en
Not available
Field of research list names fr
Non disponible
Socioeconomic objective list names en
Not available
Socioeconomic objective list names fr
Non disponible
Application title
Quantum sensors for biophysical modelling of brain function
Keywords
biophysical modelling; brain imaging; cognitive neuroscience; development; magnetoencephalography; neuropharmacology; neurophysiology; optically pumped magnetometers; quantum sensors
Application summary
Brain disorders represent the biggest challenge for 21st century healthcare, with a barrier to effective management being a lack of technologies to objectively assess brain health and disease. In many conditions the underlying issue is functional, due to pathological brain electrochemistry. This is harder to measure and the gold-standard for measuring brain electrochemistry is to place electrodes in the brain, which is highly invasive. Non-invasive techniques rely on measuring electrical signals at the scalp (EEG) or magnetic fields generated by neural currents (MEG). EEG has a limited spatial resolution and sensitivity to 'high-frequency' signals which are markers of healthy brain function. MEG has a good spatial precision, yet classic systems lack sensitivity and practicality. Quantum enabled magnetic field sensors - called optically pumped magnetometers - promise game-changing advancements in assessment of brain function, lifting the restrictions surrounding MEG, with simulations showing that OPM-MEG could rival the sensitivity of invasive techniques. This increased SNR also comes at a low cost, increased practicality, and greater scan tolerability, even enabling head-free movement. Our vision is to develop a quantum sensor-based imaging system for biophysical modelling of brain data, enabling electrophysiology with precision and sensitivity not possible before in non-invasive imaging, improving mathematical modeling of brain data, elucidating the electrochemical activity that underlies functioning. We will build the first quantum enabled scanner tailored to biophysical modelling and develop algorithms to exploit this increased sensitivity, testing our new system in two ways: first, in a neuropharmacological study of brain chemistry with alcohol administration. Second, we will measure how brain chemistry matures across development. These studies will prove the principle and value of biophysical modelling, exploiting the unique capabilities of quantum sensors for brain function. Ultimately, this will be transformative in human neuroscience and the technology we develop will find use in drug development, improving success rates in clinical trials, and moving the needle on precision medicine.